Hip kinetics during gait are clinically meaningful outcomes in young boys with Duchenne muscular dystrophy

Gait and Posture

Volumn 48, Issue , 2016, Pages 159-164

  Heberer, Kent ^a   Fowler, Eileen ^a   Staudt, Loretta ^a   Sienko, Susan ^b   Buckon, Cathleen E ^b   Bagley, Anita ^c   Sison Williamson, Mitell ^c   McDonald, Craig M ^c,d   Sussman, Michael D ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SHRINERS HOSPITAL FOR CHILDREN   (United States)

^c SHRINERS HOSPITALS FOR CHILDREN NORTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Corticosteroids; Duchenne muscular dystrophy; Gait analysis; Kinetics; Outcome measure

Indexed keywords

CORTICOSTEROID;

ARTICLE; CHILD; CLINICAL ARTICLE; DUCHENNE MUSCULAR DYSTROPHY; GAIT; HIP KINETICS; HUMAN; KINEMATICS; KINETICS; MALE; MUSCLE WEAKNESS; PRIORITY JOURNAL; WALKING SPEED; BIOMECHANICS; HIP; MUSCLE STRENGTH; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHYSIOLOGY; PRESCHOOL CHILD;

BIOMECHANICAL PHENOMENA; CHILD; CHILD, PRESCHOOL; GAIT; HIP JOINT; HUMANS; KINETICS; MALE; MUSCLE STRENGTH; MUSCULAR DYSTROPHY, DUCHENNE; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84971372948     PISSN: 09666362     EISSN: 18792219     Source Type: Journal    
DOI: 10.1016/j.gaitpost.2016.05.013     Document Type: Article

References (30)

1. Hoffman E.P., Bronson A., Levin A.A., S'ichi Takeda, Yokota T., Baudy A.R., et al. Restoring dystrophin expression in Duchenne muscular dystrophy muscle. Am. J. Pathol. 2011, 179:12-22.
2. Beenakker E.A.C., Maurits N.M., Fock J.M., Brouwer O.F., van der Hoeven J.H. Functional ability and muscle force in healthy children and ambulant Duchenne muscular dystrophy patients. Eur. J. Paediatr. Neurol. 2005, 9:387-393.
3. McDonald C.M., Abresch R.T., Carter G.T., Fowler W.M., Johnson E.R., Kilmer D.D., et al. Profiles of neuromuscular diseases: Duchenne muscular dystrophy. Am. J. Phys. Med. Rehabil. 1995, 74:S93.
4. Sutherland D.H., Olshen R., Cooper L., Wyatt M., Leach J., Mubarak S., et al. The pathomechanics of gait in Duchenne muscular dystrophy. Dev. Med. Child Neurol. 1981, 23:3-22.
5. Hsu J.D., Furumasu J. Gait and posture changes in the Duchenne muscular dystrophy child. Clin. Orthop. 1993, 288.
6. Bushby K., Finkel R., Birnkrant D.J., Case L.E., Clemens P.R., Cripe L., et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010, 9:77-93.
7. Scully M.A., Pandya S., Moxley R.T. Review of Phase II and Phase III clinical trials for Duchenne muscular dystrophy. Expert Opin. Orphan Drugs 2013, 1:33-46.
8. Balaban B., Matthews D.J., Clayton G.H., Carry T. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect. Am. J. Phys. Med. Rehabil. 2005, 84:843-850.
9. Henricson E.K., Abresch R.T., Cnaan A., Hu F., Duong T., Arrieta A., et al. The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures. Muscle Nerve 2013, 48:55-67.
10. Mendell J.R., Moxley R.T., Griggs R.C., Brooke M.H., Fenichel G.M., Miller J.P., et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N. Engl. J. Med. 1989, 320:1592-1597.
11. Angelini C. The role of corticosteroids in muscular dystrophy: a critical appraisal. Muscle Nerve 2007, 36:424-435.
12. Kornegay J.N., Spurney C.F., Nghiem P.P., Brinkmeyer-Langford C.L., Hoffman E.P., Nagaraju K. Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials. ILAR J. 2014, 55:119-149.
13. Wagner K.R. Approaching a new age in Duchenne muscular dystrophy treatment. Neurotherapeutics 2008, 5:583-591.
14. Lynn S., Aartsma-Rus A., Bushby K., Furlong P., Goemans N., De Luca A., et al. Measuring clinical effectiveness of medicinal products for the treatment of Duchenne muscular dystrophy. Neuromuscul. Disord. 2015, 25:96-105.
15. Haas M., Vlcek V., Balabanov P., Salmonson T., Bakchine S., Markey G., et al. European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene. Neuromuscul. Disord. 2015, 25:5-13.
16. Lu Q.-L., Yokota T., S'ichi Takeda, Garcia L., Muntoni F., Partridge T. The status of exon skipping as a therapeutic approach to Duchenne muscular dystrophy. Mol. Ther. 2011, 19:9-15.
17. McDonald C.M., Henricson E.K., Han J.J., Abresch R.T., Nicorici A., Elfring G.L., et al. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve 2010, 41:500-510.
18. Scott E., Eagle M., Mayhew A., Freeman J., Main M., Sheehan J., et al. Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy: development of a scale for Duchenne MD. Physiother. Res. Int. 2012, 17:101-109.
19. Kirschner J., Schessl J., Schara U., Reitter B., Stettner G.M., Hobbiebrunken E., et al. Treatment of Duchenne muscular dystrophy with ciclosporin A: a randomised, double-blind, placebo-controlled multicentre trial. Lancet Neurol. 2010, 9:1053-1059.
20. Lu Q., Cirak S., Partridge T. What can we learn from clinical trials of exon skipping for DMD?. Mol. Ther. Acids 2014, 3:e152.
21. Wren T.A.L., Gorton G.E., Õunpuu S., Tucker C.A. Efficacy of clinical gait analysis: a systematic review. Gait Posture 2011, 34:149-153.
22. Gaudreault N., Gravel D., Nadeau S., Houde S., Gagnon D. Gait patterns comparison of children with Duchenne muscular dystrophy to those of control subjects considering the effect of gait velocity. Gait Posture 2010, 32:342-347.
23. D'Angelo M.G., Berti M., Piccinini L., Romei M., Guglieri M., Bonato S., et al. Gait pattern in Duchenne muscular dystrophy. Gait Posture 2009, 29:36-41.
24. Armand S., Mercier M., Watelain E., Patte K., Pelissier J., Rivier F. A comparison of gait in spinal muscular atrophy, type II and Duchenne muscular dystrophy. Gait Posture 2005, 21:369-378.
25. Doglio L., Pavan E., Pernigotti I., Petralia P., Frigo C., Minetti C. Early signs of gait deviation in Duchenne muscular dystrophy. Eur. J. Phys. Rehabil. Med. 2011, 47:587-594.
26. Sienko Thomas S., Buckon C.E., Nicorici A., Bagley A., McDonald C.M., Sussman M.D. Classification of the gait patterns of boys with Duchenne muscular dystrophy and their relationship to function. J. Child Neurol. 2010, 25:1103-1109.
27. Mazzone E., Vasco G., Sormani M.P., Torrente Y., Berardinelli A., Messina S., et al. Functional changes in Duchenne muscular dystrophy A 12-month longitudinal cohort study. Neurology 2011, 77:250-256.
28. M.C.Donald C.M., Henricson E.K., Han J.J., Abresch R.T., Nicorici A., Atkinson L., et al. The 6-minute walk test in Duchenne/Becker muscular dystrophy: longitudinal observations. Muscle Nerve 2010, 42:966-974.
29. Ergun N., Tunay V.B., Baltaci G. Health-related physical fitness levels of Turkish kindergarten children: a three-year follow up. Age Mon 2006, 34:5-6.
30. Chester V.L., Tingley M., Biden E.N. A comparison of kinetic gait parameters for 3-13 year olds. Clin. Biomech. 2006, 21:726-732.